Daniel Low

Daniel Low

Auto-generated profile, based on publicly available information

Daniel Low

Washington University, Saint Louis, Mo

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2024 in medRxiv
Verified
Preprint
Open access
PDF file
SWScott Wilkinson
Scott Wilkinson
AKAnson T. Ku
Anson T. Ku
RLRosina T. Lis
Rosina T. Lis
IKIsaiah M. King
Isaiah M. King
DLDaniel Low
Daniel Low
ASAdam G. Sowalsky
Adam G. Sowalsky
Patients diagnosed with localized high-risk prostate cancer have higher rates of recurrence, and the introduction of neoadjuvant intensive hormonal therapies seeks to treat occult micrometastatic disease by their addition to definitive treatment. Sufficient profiling of baseline disease has remained a challenge in enabling the in-depth assessment of phenotypes associated with exceptional vs. poor pathologic responses after treatment. In this study, we report comprehensive and integrative gene expression profiling of 37 locally advanced prostate tumors prior to six months of androgen deprivation therapy (ADT) plus the androgen receptor (AR) inhibitor enzalutamide prior to radical prostatectomy. A robust transcriptional program associated with HER2 activity was positively associated with poor outcome and opposed AR activity, even after adjusting for common genomic alterations in prostate cancer including PTEN loss and expression of the TMPRSS2:ERG fusion. Patients experiencing exceptional pathologic responses demonstrated lower levels of HER2 and phospho-HER2 by immunohistochemistry of biopsy tissues. The inverse correlation of AR and HER2 activity was found to be a universal feature of all aggressive prostate tumors, validated by transcriptional profiling an external cohort of 121 patients and immunostaining of tumors from 84 additional patients. Importantly, the AR activity-low, HER2 activity-high cells that resist ADT are a pre-existing subset of cells that can be targeted by HER2 inhibition alone or in combination with enzalutamide. In summary, we show that prostate tumors adopt an AR activity-low prior to antiandrogen exposure that can be exploited by treatment with HER2 inhibitors. ClinicalTrials.gov registration: NCT02430480 .

11 June 2007 in Medical Physics
Verified
Journal Article
Closed access
DLD Low
D Low
PPP Parikh
P Parikh
JHJ Hubenschmidt
J Hubenschmidt
SMS Mutic
S Mutic
JDJ Dempsey
J Dempsey
JBJ Bradley
J Bradley

1 June 2006 in Medical Physics
Verified
Journal Article
Closed access
JRJ Repp
J Repp
WLW Lu
W Lu
JHJ Hubenschmidt
J Hubenschmidt
PPP Parikh
P Parikh
SMS Mutic
S Mutic
DLD Low
D Low

11 June 2007 in Medical Physics
Verified
Journal Article
Closed access
DLD Low
D Low
PPP Parikh
P Parikh
BWB Whiting
B Whiting
SMS Mutic
S Mutic
JHJ Hubenschmidt
J Hubenschmidt
JBJ Bradley
J Bradley

1 September 2004 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
PDF file
WLWei Lu
Wei Lu
PPP. Parikh
P. Parikh
IEI. ElNaqa
I. ElNaqa
MNM. Nystrom
M. Nystrom
JHJ. Hubenschmidt
J. Hubenschmidt
DLD. Low
D. Low
The process of four-dimensional computed tomography (4D CT) uses multislice CT scans that have been sorted or gated using a metric, spirometry in our case. The purpose of this work is to quantify the reconstructed dataset quality and especially the level of correlation between spirometry and internal-object motion. Good correlations will imply that CT reconstructions and motion measurements will be precise and accurate for treatment planning purposes.